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Abstract
Introduction and hypothesis The aim of this study was to identify modifiable factors to improve recruitment in a urology clinical
trial of women with recurrent urinary tract infection (rUTI). An embedded qualitative study was conducted with patients and
recruiting clinicians in the first 8 months of the trial.We present a matrix of factors influencing how patients make decisions about
trial participation.
Methods This was a qualitative study using telephone interviews. When they were first approached about the trial, women were
asked to complete an expression of interest form if they wished to be contacted for an interview. Data were analysed thematically.
NVivo 10 software (Qualitative data analysis software. 10th ed: QSR International Pty Ltd; 2012) was used as a management
tool.
Results Thirty patients and 11 clinicians were interviewed. Influences on patient participation included the impact of rUTI on
quality of life (QoL), understanding of antibiotic resistance, and previous experiences with antibiotics either positive or negative.
Very few women who declined the trial agreed to be interviewed. However, some of those who participated had reservations
about it. These included the perceived risk of trying a new treatment, trial length, and the burden of participating. One person
interviewed left the trial because of repeated infections and difficulties getting general practitioner appointments.
Conclusions A combination of factors worked to influence women to decide to participate, to remain in, or to leave the trial. A
better understanding of how these factors interact and work can assist in the recruitment and retention of individual trial
participants.
Keywords Recurrent urinary tract infection . Clinical trials . Qualitative researchmethods . Recruitment
Introduction
Achieving patient recruitment and accrual targets is essential
for the success of randomised controlled trials (RCTs), the
current gold standard in clinical research [1]. Efforts to im-
prove these factors have included trials on recruitment strate-
gies [2] and interventions to improve informed consent [3]. A
systematic review of strategies to improve trial recruitment
highlighted the importance of raising patients’ understanding
of their health problem and how it impacts them [2].
Qualitative interventions to improve informed consent have
provided a means to understanding recruitment difficulties
and how to overcome them [3]. As a result, the design of trial
processes has undergone a number of improvements, such as
inclusion of qualitative methods to identify and overcome
barriers to recruitment [4] and, to keep pace with changing
societal norms, to explore patient expectations and prefer-
ences, but further work is needed in this area.
Retaining participants in a clinical trial is another area of
focused research [5, 6]. Zweben et al., for example, proposed a
list of tailored routine and non-routine strategies to address the
different risk levels of protocol adherence [5]. Some practical
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examples include obtaining permission to re-contact at a later
time by sending strategic letters or e-mails. The importance of
communication skills that engender ongoing trust has also
been highlighted [6]. Underlying these attempts was the quest
to understand decision-making processes about trial participa-
tion [7, 8], which were found to be influenced by the trial
being directly relevant to individual patient circumstances,
comfort and safety being carefully considered [7]. Other fac-
tors were strong individual treatment preferences for aspects
of the trial, and these factors were often influenced by person-
ality traits [8]. The social actors in this context are patients and
the trial recruiter. The focus of the information being ex-
changed is in the context of trial design and process.
Addressing an identified gap in knowledge, research has
been conducted into the experiences of trial staff [9, 10].
Specific research into the experiences of trial recruiters uncov-
ered the need for more training, for example, in exploring
treatment preferences in more depth rather than requiring par-
ticipants to accept them at face value and closing off further
discussion [11]. At the organisational level, there has been
qualitative research with staff, investigating the barriers and
facilitators that can take the form of norms, structures and
processes present in the conduct of trials, and competitive
pressures to perform well, resulting in inducements and en-
hanced care for patients [12, 13]. A review of the literature has
raised the issue of over-emphasis on barriers to recruitment to
the neglect of assessing facilitators, as found in successful
trials [4]. The literature emphasises the need for more engage-
ment of patients in understanding the trial and its processes
[14–16]. Apart from the lack of patient-centred interaction in
discussion of the trial [17], other barriers to recruitment relate
to participant co-morbidities, particularly in older people; their
impact on the practicalities of participating [18]; and the lo-
gistics of journey length [19]. In one approach to trial recruit-
ment using patients’ risk–benefit assessments, patients’ deci-
sions were context-dependent [20], especially if the benefit of
close monitoring by specialists was opposed to their poor
access to specialist services outside trial participation. The
need for a more in-depth investigation of both decision mak-
ing about UTI prophylaxis [21] and in recruitment into uro-
logical trials in primary care [7] is also highlighted.
We report on a qualitative study embedded in a clinical trial
investigating the effectiveness of non-antibiotic prophylaxis
for recurrent urinary tract infection (rUTI) in women. The
aim of the embedded qualitative study was to inform the study
team of potential barriers to recruitment and retention in the
first 8 months of recruitment. This study adds to the knowl-
edge around participant decision-making processes about pro-
phylactic treatment and participation in urological trials.
Alternatives to Prophylactic Antibiotics for the Treatment
of Recurrent Urinary Tract Infection in Women (ALTAR) is a
multicentre, pragmatic, patient-randomised, non-inferiority
trial comparing two treatments for preventing rUTI in women
during a 12-month period of treatment and in the 6 months
following treatment completion. Standard treatment is once-
daily prophylactic antibiotic administration of licenced drugs
recommended for this purpose: trimethoprim 100 mg,
nitrofurantoin 50 or 100 mg or cefalexin 250 mg. The choice
of antibiotic is determined by considering previous bacterial
sensitivities, safety and patient or clinician preference. The
alternative (experimental) treatment is 1 g per os twice daily
of the urinary antiseptic methenamine hippurate (Hiprex) for
12 months. Participants in both arms would continue to re-
ceive treatment courses of antibiotic for UTI as needed.
The trial (including the embedded qualitative study) re-
ceived a favourable ethical opinion from the North East -
Tyne & Wear South Research Ethics Committee (Ref: 15/
NE/0381). This research was funded by the UK National
Institute of Health Research’s Health Technology Assessment
Programme and was a commissioned call.
Methods
Recruitment to the qualitative study
Recruiting staff (trial nurses and doctors) introduced the quali-
tative study when women were approached about the ALTAR
trial. All women who were eligible for the trial were asked to
participate in the qualitative work, including those who had
expressed a desire not to participate in the study. Recruiters
explained the importance of understanding why people do
and do not participate and how we sought to improve the way
trials are conducted. Patients willing to be approached about the
qualitative study were provided with a separate information
sheet and contact form (expression of interest) in a reply-paid
envelope to complete and return to the clinical trials unit (CTU).
The CTU informed the qualitative team of all patients willing to
be approached about an interview (including those who later
left the trial). The aim was to conduct semi-structured inter-
views with patients within 2 weeks of the initial approach.
Where possible, a second interview was conducted 3–6 months
later to capture participants’ views on trial processes, outcome
measures and reasons for leaving the trial. Clinicians [research
nurses (RN) and principal investigators (PI)] were approached
via e-mail a month after recruitment commenced at their site.
Data collection
Patients who completed and returned a contact form were
telephoned to answer any questions they may have about the
qualitative study and to provide consent to participate; if they
were happy to participate, a date and timewas arranged for the
interview. Most preferred to be interviewed when first
contacted. Telephone interviews were conducted using topic
guides developed with the input of the study team and Patient
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and Public Involvement group. Questions addressed partici-
pants’ experiences of trial recruitment and conduct, as well as
acceptability of the intervention for both patient and clinician.
Modifiable factors identified were noted immediately after the
interview and fed back to the trial management group or chief
investigator and CTU team. The interviews, prefaced by in-
formed consent, were carried out by co-authorsMLSL and JL,
digitally recorded with the permission of the interviewee and
transcribed verbatim.
Analysis
Interview transcripts were checked and anonymised. Data was
analysed drawing upon the constant comparative method, and
a thematic coding frame was agreed upon between JL and
MLSL. NVivo was used as a tool to manage and code tran-
script data, which was stored on password-protected drives.
The overall headline results were made available to inform
change in study procedures before the end of the first year of
the recruitment phase.
Results
Participants
Between July 2016 and March 2017, 77 patients agreed to
participate in the trial and were randomised. Eighteen were
required to complete a washout period, as per protocol, as they
had previously had prophylactic antibiotic treatment for rUTI.
Thirty-five expression-of-interest forms were received for the
qualitative study, and 30 participants were interviewed. One
patient had already been approached about the trial but was
deemed unsuitable because of confidential health reasons; as
this person had some useful comments about the investiga-
tional medicinal products, their views are reported in this pa-
per. Eleven RNs and two consultants (COs) were also
interviewed. Eleven patients had a follow-up interview 3–
6 months after the first interview (Table 1).
The sample was diverse in that there was a wide range of
ages—from teenage to 80+; 12 patients had partners, and five
were single. Three patients discussed the trial with a health
professional only; the remainder did so with their partners or
family and friends. Experience of rUTI ranged from 2 years to
a life-long chronic condition; many could be defined as
Bexpert patients^ (RN103). Only three had previously partic-
ipated in research.
Alerts to trial team
Issues identified that could impact recruitment and were re-
solvable included lack of clarity in the patient study informa-
tion or consent process. The immediate feeding back of these
issues enabled the chief investigator and trial team to rapidly
resolve these issues. Some issues included whether adverse
events (AEs) or severe adverse events (SAEs) reported by
interviewees had been recorded in the trial data.
Views of the trial
Themes
The interviews were driven by the need to explore factors
around the trial processes and conduct: for example, views
on trial information and consent process for both patients
and recruiting staff. However, additional data was obtained
on other themes identified, such as experience of rUTIs and
their management and views of taking antibiotics.
Was the trial information comprehensive?
Patients recruited into the trial were provided with an infor-
mation booklet covering the purpose of the study, the reason
they were invited to participate, randomisation, the benefits
and disadvantages or risks of taking part, the side effects of the
drugs and patient confidentiality. Most patients were happy
with the way information was conveyed to them verbally by
the RN and appreciated the ongoing support they provided.
The written information also provided reassurance and could
be shared with family. However, some patients had queries
about the actual workings of the trial drugs. In one of the first
Table 1 Detailsof participants approached for the qualitative study
Patients and recruiters
Trial participants 27a
Randomised to:
Antibiotic 16
Methenamine 12
Second interview conducted 11b
Randomised to:
Antibiotic 5
Methenamine 6
Interviewee unsuitable for trial 1
Interviewee declined trialc 1
Not contactable 5
Recruiting staff
Research nurses 7
Consultants 2
Non-contactable 5
a Experienced an antibiotic washout period prior to trial entry - 1 patient
b Number of breakthrough infections recorded - 12
c Participant declined the trial was on Hiprex but stated she was willing to
be contacted again, as she was very interested in the effects of the drug
and the research we were conducting
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interviews, an interviewee raised a question about what was
meant by an antiseptic as opposed to an antibiotic (this was
reported to the Trial Management Group). These are common
terms in the biomedical vocabulary that may be imprecise to a
layperson, who then resorts to the Internet to find out how the
medication works [Patient (PAT)1008], including how its
mechanisms of action could be improved [Table 3, quotation
1 (Q1)]. It was asserted by clinicians that most patients were
familiar with the idea of taking prophylaxis, commonly un-
derstood as a low dose of antibiotic to stave off infection.
Nevertheless, the expectations of the treatments in question
caused some questions to be raised about whether patients
had a correct understanding about the trial drugs. Some ap-
peared to believe that the trial would find the root problem and
cure the condition (Q2-4). Patient beliefs and attitudes can
contribute to the willingness to participate and stay in a trial
[18]. However, it is important that they be based on an ade-
quate understanding of the workings of the trial drugs. This
was fed back to the trial team to improve the preliminary
counselling process.
Why are patients willing participants?
From interviews with both patients and clinicians, there was
agreement that the patient cohort were generally willing par-
ticipants for a number of reasons, the most prevalent being the
desperation to find a solution to their problems. One inter-
viewee summed up the impact of rUTIs on normal activities
in her daily life (Q5). Most interviewees were informed about
antibiotic resistance, but their participation in the trial was
described by clinician interviewees as clutching at straws
(RN1301) – (Q6-7). For patients who had been recipients of
healthcare for other conditions, there was also the desire to
reciprocate. Others referred to the chance to help themselves
and at the same time help others in the course of the research
as fuelling their reasons to join the trial. Some patients were
persuaded by the extra monitoring they would receive as trial
participants (Q8) and that the course of treatment they re-
ceived would be no different to standard care (Q9).
Interestingly, women also referred to concerns about antibi-
otics. Although ultimately not eligible for the trial, one patient
who had taken one of the trial medications as part of routine
care and was told it was an alternative to an antibiotic had
searched for information (Q10-11). Some had prior problems
with certain antibiotics taken in the past (Q12). Others were
aware that one could develop a resistance to antibiotics if
taken for an extended period and appreciated the chance to
try an alternative (Q13).
Why may patients have reservations about the trial?
The aim was to speak to up to 15 patients who had declined
and 15 who dropped out of the trial to determine their reasons,
yet the recruitment of such patients to the qualitative study was
difficult. Despite the fact that 60 patients declined to partici-
pate in the trial, only one returned an expression-of-interest
form to be interviewed. This patient declined the trial, prefer-
ring not to take antibiotics for an extended period (Q14). To
explore reasons for non-participation, screening logs were
analysed for patients who declined the study (Table 2) within
the time frame during which the qualitative work was under-
taken. These reasons were reinforced in the interviews with
clinicians and in patient/participant reservations about the trial.
Despite the low number of interviews with those who de-
clined, data from patient and clinician interviews pointed to a
number of reasons patients may not be willing to participate in
the trial. One reason given by recruiting clinicians was that
women were unwilling to try something new and different,
especially if a particular treatment was working well for them
or if they had no UTI at that time (Q15-16). This suggested
that such women wanted to Blet sleeping dogs lie^ and were
not willing to take unnecessary risks. Table 2 demonstrates a
number of women declined to participate because of the 3-
month washout period if already on prophylaxis. This view
was reinforced in the clinician interviews (Q17-18) as a fear of
causing further UTIs. Clinicians also cited practical difficul-
ties for patients, which could include attending appointments,
being non-compliant with the drug regime or had lives com-
plicated by other on-going health conditions (Q19).
Why might patients consider dropping out?
During the qualitative study, eight patients withdrew from the
trial. One patient in the antibiotic armwas interviewed just after
withdrawal and gave the reason as being repeat infections and
difficulties with general practitioner (GP) appointments.
Another reason was an underlying preference for a particular
treatment, even though at the time of recruitment randomisation
was accepted by the particular research participant (Q20). In
most interviews, relatives of patients appeared to express sup-
port for their decision to enter the trial. In contrast, one patient
reported her family and friends were concerned about her being
on antibiotics for a whole year, yet she understood the
Table 2 Screening log data: reasons for declining the trial
Reasons specific to trial Other
Aspects of trial medications involved 4 No reason given 22
Blood tests 1 Not interested 6
Washout 7 Moving out of area 1
Extended follow-up period 4 Other health problems 5
Inability to adhere to trial protocol 2 Feels well 3
Also recorded on the screening log were four patients who could not be
contacted and one who did not attend the appointment with the research
nurse
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importance of the time needed to test the effectiveness of the
drug being trialled. Treatment effect and trial length were other
reasons given (Q21). This could combine with treatment pref-
erence to tip the balance for the participant to withdraw (Q22).
Apart from some patients forgetting to take their trial medica-
tion, a number of patients reported difficulties taking the tablet
due to its size and taste. One patient resorted to halving the
tablet to make it more manageable, and: Bto get rid of the taste,
I would reward myself with something sweet afterwards^ (pa-
tient 1009). Although no one left the trial specifically due to
difficulty taking the tablets, it could potentially be a contribut-
ing factor to non-adherence to trial procedures and possibly
leaving the trial.
Most requirements of the trial were not too different to the
regular pathway for such patients. However, research burdens
placed upon participants were identified that could accumulate
during the course of the trial to discourage commitment to
processes (Q23-24). One such burden, especially for the el-
derly and infirm or those with busy work schedules, was the
effort of getting the sample to their GP (Q25) Table 3.
A matrix to understanding trial participation
These findings led us to devise a matrix (Fig. 1) to highlight
and explain the interactions of influences on the decision-
making process of women about continuing on this trial.
While women with no real preference for either treatment
are ideal candidates for a randomised controlled trial, there
are many who may harbour a weak preference but are still
willing to be randomised.
Those concerned about antibiotic resistance and/or who
have had negative experiences taking antibiotics—for exam-
ple, side effects like gut problems or thrush—may lean to-
wards a slight preference for the antiseptic. If they experience
a heavy research burden, for example, because of age, and/or a
reduced ability to adhere to the trial and drug regime, the
combined effect of these factors could likely push them to
leave the trial prematurely. On the other hand, those who hold
slight concerns about the new drug being tested and/or have
had a good experience with antibiotics, especially as a pro-
phylaxis, may hold a slight preference for antibiotics. Any
Table 3 Interview questions and quotations (Q) from interviewees
Questions and quotation
number
Interviewee response
Was the trial information comprehensive?
Q1 I just wondered whether, like, a pH test… once you know that you are on the Hiprex, whether a pH test might be useful to
see how acidic your urine is……Because what I read was that a lot of doctors recommend taking a vitamin C tablet at the
same time as the Hiprex - PAT1018
Q2 Some women have heard about being on prophylactic, some of them have been on prophylactics already. But obviously,
they understand it. I mean, you’re not having to teach them what prophylactic means and things like that, they all
understand it. - RN1301
Q3 I feel bad with it, it does affect your whole life. So I wasmore than happy to go for the trial and try and seek it out, for want of
a better word. - PAT1101
Q4 …on my second visit, when I went to collect the medicine, they said...um...they told me that if I had another infection, to go
and see my GP. But I thought that this treatment would stop them altogether, so I was bit concerned about that at the
beginning - PAT1008
Why are patients willing participants?
Q5 I think a lot of people do not understand a UTI, they just kind of think waterworks.…But when it’s something, you know,
basic things like walking. Walking, sleeping, sitting at work, having a conversation with people, when you have got that
level of discomfort, it’s difficult to just carry on as normal, to be honest. So yes, it really does affect your quality of life -
PAT1005
Q6 I am at a stage now where I am actually prepared to try anything to try and rectify this, if possible - PAT1011
Q7 As I say, I am pulling my hair out with this repeating occurrence with the infection and that so if I can do anything more
hopefully-helpful - PAT1101
Q8 So for me it was like, I would be getting medication anyway, so I can get the same medication and be slightly closer
monitored for the problem I was having – PAT1009
Q9 I thought if I can be part of research and get treatment and research can be done at the same time to sort of help women that
are going through the same thing, I thought it’s a positive thing.- PAT1013
Q10 I started taking these and I was a little bit concerned. So I actually got on the Internet and researched this and it actually says
that it is an antibiotic. So I was a little bit confused. - PAT1005
Q11 Well, I suppose I was worried about, what is this that I’m putting in my system? What effect is it having on me? Because
when you read it turns into formaldehyde you’re like, BOh my god is that actually good for me or not, I don’t know. -
PAT1005
Q12 Specifically in terms of the UTIs, I am already allergic to penicillin, so I can see the, you know, for me, the use of antibiotics
is already quite limited. So I can see the benefit of trialling other ways, you know, for people like myself. - PAT1018
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problems arising from the research burden and/or ability to
adhere to trial requirements could then nudge them in the
direction of leaving the trial. Women with no preference for
either treatment could still be influenced by these factors in-
dependently, which includes the effect of the treatment on
their condition during the course of the trial.
Table 3 (continued)
Q13 I’m kind of glad that I was put on the antiseptic rather than antibiotic just because I know that obviously prolonged use of
antibiotics, you can build up resistance to it - PAT1013
Why may patients have reservations about the trial?
Q14 I do not think it’s healthy to take antibiotics for 12months, I do not think the effect on your body is a positive one…. I just, I
did not want to take them, I did not want to be selected for the route of antibiotics for 12 months. - PAT1014
Q15 That it is a trial puts them off, just the fact that we are a trial or study. It makes them think they are trying something new or
different - CO1102
Q16 I have had some ladies that have said that since they have been to the hospital they have not had any urinary tract infections.
So they’re not wanting to take part in the study just now because they’re quite, you know, everything’s going well for them
and they do not feel the need to do anything extra at the moment. - RN1301
Q17 They’re scared not to have their treatment because for them the prophylactic antibiotics may be working to a point. They
don’t necessarily want to come off of them and not have treatment. - RN1101
Q18 .^…. I think a lot of themwould be rather hesitant to take on, or to stop, because actually for the first time in ages, they have
got something that’s working. - CO1303
Q19 For whatever reason, their lives are chaotic or they’re unwell. I mean, I have had quite a few women, there’s a couple of
women that have been diagnosed with cancer. And they’re not wanting, they’re just like, BI can’t think about anything else
right now.^ RN1301
Why might patients consider dropping out?
Q20 Interviewer: Would you have come off the trial if you were given the antibiotic, do you think?
Patient: No, I don’t think I would have. I would have continued with it and given it a try but I think I would have been very
open to, more open to saying, BWell, if this is not working I’m just coming off it,^ whereas with this one I want to
participate until the time is up if I can. – PAT1020:
Q21 One of my main concerns was that a year was a very long time to do a treatment………my worry about the antibiotic was
that maybe it was too long, and there might be some damage to the stomach lining. With such a heavy, it’s not heavy
obviously, it’s a small dose but it’s for a long time. – PAT 1008
Q22 I thought if I get the antibacterial, which I would have gone through, but if it made life not much better, it would have seemed
a long drag. The year would have been a long year . – PAT1016
Q23 One of the things that we have found for the ladies that have taken part in the study is trying to get their head around the
system of sending back samples if they have a urinary tract infection. The process of the paperwork, the pods that they have
to put the samples in, we have had a problem with that. I do not know whether the people declining do not want any
additional hassle, additional visits, additional medication. - RN1302
Q24 And we have had one lady already come off study, because she thought it would be a burden as well, after having initially
being recruited. - RN1002
Q25 The biggest inconvenience is getting it to the doctors…. because of the hours that I work, it impacts on my working life....
Because you have got to be there before a certain time so that the carrier can get it down to the hospital. – PAT1011FU
Q quote number, PAT patient, RN research nurse, CO consultant, FU follow-up
Concerns about anbioc 
resistance
Concerns about HIPREX 
(cf informaon etc)
Preference for ansepc Preference for anbioc
Paent decision-making about trial parcipaon
Negave experiences 
with anbiocs
Posive experiences with 
anbiocs
Experience of research burden Ability to adhere to trial and 
drug regimen
Treatment effects
Fig. 1 Matrix of factors for trial
participation
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Discussion
The notion that RCTs offer the best means of assessing the
clinical and cost effectiveness of medical interventions has been
under scrutiny for a number of years. This is because the valid-
ity and reliability of RCTs are dependent on many human fac-
tors, in particular, behaviours of clinicians, patients and the
organisational management involved in a trial [12, 13, 19].
The complex notions of randomisation and clinical equipoise
can be difficult to negotiate between trial recruiter and potential
participant [10, 22]. While the patient information sheet has
detailed information about trial procedures, there will nonethe-
less be inadvertent gaps in understanding and retention on the
part of the patient—for example, as expressed in their expecta-
tions of the trial. However, patients can still be highly motivat-
ed, even if these conditions exist, because of the impact and
length of the condition on quality of life. Treatment preferences
are complicated to ascertain [11]—for example, because of their
variability—and it is important to recognise the distinction be-
tween a patient’s preferences and her decision to be randomised
[23]. A patient may have a faint preference for participation but
still agree to be randomised because of her desperation to seek
out a suitable treatment. Altruism can come into play when
deciding to join a trial, but practical concerns and difficulties
can override all the good reasons for inclusion. The preference
to not disrupt existing routines that currently work well is an-
other reason for not being part of the trial, including not being
subject to what is new and possibly risky and burdensome.
If concerns about taking an antibiotic prophylaxis or the
antiseptic methenamine could be addressed by more informa-
tion about how the two kinds of drugs work as prophylactic
treatments and the risks involved, decision making about trial
participation could be improved. The patient’s past experiences
with antibiotics could form the basis for a more in-depth discus-
sion about trial participation because of the way these have been
identified as influencing the patient’s thinking about entering
and staying in the trial. These findings resonate with other work
reporting on the effect of past experiences of trial participation
[24] and contextual factors unrelated to the trial itself [20].
Finally, this research provides a detailed insight into several
aspects of the recruitment and retention process within a clin-
ical trial involving female patients with recurrent UTI. It high-
lights several areas that future trials may want to consider
when trial methodologies are designed. One aim of this re-
search was to contribute to the literature on patient and clini-
cian experiences of trial processes, and we identified some
common themes: trial information, reasons for participation
and reservations about taking part.
Study limitations
For the 8-month duration of the embedded qualitative study,
the ALTAR trial opened in five sites, a number of which did so
towards the end of that period. The sample is thus skewed
towards the first site to open. This impacted upon the ability
of the qualitative study to have representation across the other
four sites. We were unable to interview many patients who
declined participation in or left the main trial. It is not clear
whether this was due to an unwillingness to be interviewed or
to site staff sometimes neglecting to mention the qualitative
study. Nevertheless, we incorporated an interrogation of
screening logs to gain any additional information from this
patient group. Finally, inferences made from secondary
sources (reports or reflections from clinicians) may not be as
reliable as self-reported patient data.
Conclusion
Trial recruitment, retention and research-study accrual are fun-
damental to the success of clinical trials. Our study contributes
insights into the way factors identified in other studies come
together to impact how patients decide to enter, stay or leave a
trial.
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